From among the IL-6 options, tocilizumab—formally included in the National Health Commission of China’s COVID-19 diagnosis and treatment program, and recently, in Infectious Diseases Society of America—is an IL-6 receptor antagonist that inhibits signal transduction by binding sIL-6R and mIL-6R and can be used in patients with bilateral pneumonia from SARS-CoV-2 [86]. This evidence concerns the gene IL6 and susceptibility to pneumonia measurement.